Financial intelligence for Asia's healthcare markets
Remember me:

Analysis: Winners and losers in South Korea

The ambitious healthcare agenda under Moon Jae-in's liberal presidency will seek to expand national health insurance reimbursement and limit the burden of excessive medical costs, while overhauling the healthcare system. BMI Research looks at the winners and the losers in the presidential agenda.

The healthcare agenda of President Moon Jae-in of the Minjoo (Democratic) Party, who took office in May 2017, will aim to increase the role of the public sector in the healthcare system and expand national health insurance reimbursement cover to reduce the burden of high medical costs, including an annual cap of W1 million (US$862) on patient contributions to medical care costs for citizens on low incomes. In order to secure the long term sustainability of the healthcare system, the president will seek to move the focus of healthcare delivery from large hospitals to cheaper primary care structures. This will involve limiting the expansion of large hospitals and restricting the number of small and medium supply hospitals, some of which will be encouraged to convert into specialised institutions.

In August 2017, President Moon Jae-in announced an investment of KRW30.6trn (USD26.4bn) over his five-year presidential terms to fund the expansion of health insurance cover to all major illnesses and to pay for costs that are currently uninsured such as specialist appointments and nursing care. Reimbursement for technical aids such as dental implants and hearing aids will also improve. The government estimates that full implementation of its plans would reduce personal spending on medical care costs by an average of nearly one fifth by 2022, with a reduction of nearly half for citizens on lower incomes.

We note that South Korea has an unusually high level of private sector health funding for an OECD country and the level continues to grow. In 2017, we estimate that the private sector will fund 46.7% of total healthcare expenditure of W131.7 trillion (US$113.5 billion), up from 43.3% in 2010. More than three-quarters of private health spending is in the form of out-of-pocket payments.

In order to achieve long term financial sustainability, the government will seek to limit the amount of hospital based outpatient care in favour of more cost-effective primary care services. This will increase financial pressures on hospitals and is also likely to frustrate the Ministry of Health and Welfare's plans to develop telemedicine, limiting the rollout to areas with the least developed healthcare resources.

The government's healthcare agenda has already met with fi erce opposition from healthcare providers and doctors, including the National Union of Korean Medical Doctors and the Korean Medical Practitioners Association. Healthcare providers have condemned the plans as unviable and a threat to the financial position of the health insurance system, which would either lead to a sharp increase in health insurance premiums or a drop in fees paid to medical institutions, forcing many of them bankruptcy.

We highlight that the Moon administration will struggle to fully implement its healthcare agenda given it lacks a majority in parliament, which will hinder efforts to achieve policy objectives. We note that Moon's first 100 days in government have been characterised by considerable opposition as the president struggles to implement his various campaign policies, despite persistently high public approval ratings. We therefore maintain our short term political risk score at 70.0 to reflect these difficulties.

Posted on: 03/11/2017 UTC+08:00


News

Beijing-based healthcare service platform Miaoshou Doctor has completed a ¥1.5 billion (US$232 million) Series F round of financing.
Chinese digital technology company, Xisoft Technology, which focuses on hospital operation management, has raised ¥100 million ($15.65 million) in Series A+ financing.
Hearing health company Olive Union has closed a $7M Series B round led by Beyond Next Ventures, Bonds Investment Groups and Japan Policy Finance Corporation.
Long Hill Capital, a venture capital firm in China, has closed on more than $300 million for its third fund on 15 March.
Eluminex Biosciences, an ophthalmic biotechnology company has completed a $50 million Series A financing co-led by Lilly Asia Ventures, GL Ventures (venture capital arm of Hillhouse Capital), and Quan Capital.
TVM Capital Healthcare, a global private equity and growth capital firm focused on emerging markets, has announced two team additions today.
In partnership with VeChain and DNV GL, Renji Hospital, a hospital in China affiliated with the Shanghai Jiaotong University School of Medicine, has launched the world's first blockchain-enabled intelligent tumour treatment centre.
Hong Kong-based BuyHive, a new global sourcing start-up that connects buyers with trusted verified overseas suppliers, has launched a PPE programme to help US companies optimise their post-Covid supply chains.



Analysis

L.E.K. Consulting’s Fabio La Mola tells HealthInvestor Asia about a healthcare market going through major changes – creating significant opportunities for investors in the region.
Edwin Tong, senior minister for health, explains how the Ministry of Health in Singapore is supporting the growth in the number of seniors with Alzheimer's.
Penny Wan, regional vice-president and general manager, Japan and APAC, Amgen, writes about the public health challenge of cardiovascular diseases.
French-based international ophthalmic optics company Essilor has signed Letters of Intent with the Royal Government of Bhutan and the Central Monastic Body to strengthen the country’s vision care infrastructure.
April Chang, country manager at Cigna Singapore, argues that wellness programmes at work can lead to reduced absenteeism, higher productivity and increased morale among employees.
Steven Fang understands how to set up a healthcare company. Not only is he chief executive and founder of ASX-listed oncology company Invitrocue, he was also the founder of Singapore-based Cordlife Group, a healthcare company which provides cord blood and cord lining banking services.
Imagine a world in which you can consult with your doctor via video. She asks for a blood sample, which can be collected and analysed from a device in your home. After that is diagnosed, the prescription is automatically sent to the pharmacy and Uber then picks it up. The time from diagnosis to drugs at your home is only 60 minutes.
The digitisation of health data through blockchain technology is a groundbreaking solution that will empower patients and provide them with better access to healthcare.


Podcasts

HealthInvestor Asia twitter feed










A Rolex Yacht-Master I Ladies Replica watch is basically a person watch that's crafted inside an identical fashion with a well-known maker¡¯s real piece. Purchasing Replica Watches seems as an excellent idea. Anyway,ON perfectcloneshop.com replica Rolex Yacht-Master Ladies watches are affordable, look almost the identical while using real ones and could easily acquired.